Cellebrite DI (CLBT) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- $0.02
- EPS estimate
- $0.06
- EPS surprise
- −66.33%
- Revenue surprise
- −0.28%
- Revenue
- $131.1M
- Revenue estimate
- $131.5M
- Reported
- Aug 13, 2026
Cellebrite reported Q2 2026 results on August 13, 2026. Earnings per share were $0.02, 66.33% below the $0.06 estimate. Revenue of $131.1 million was just under the $131.5 million consensus. Compared with Q2 2025, EPS fell from $0.08, while revenue rose about 16% from $113.3 million.
Revenue has trended up. The latest quarter is the highest in the table, about twice the $65.9 million of Q3 2021, and annual revenue rose about 19% in 2025 to $475.6 million. Earnings have been less steady. Annual EPS went from $0.61 in 2022 to losses of $0.43 in 2023 and $1.39 in 2024, a year that included a $0.99 loss in Q3, then back to a $0.31 profit in 2025. The first half of 2026 totals $0.06 per share, against $0.15 a year earlier. Cellebrite missed the EPS estimate in each of the last four quarters and beat it in nine of the last 20.
Q3 reports came between November 6 and November 17 in each of the past five years. That points to mid-November 2026 for the next report. It will show how EPS compares with the $0.08 earned in Q3 2025.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 13, 2026 | $0.06 | $0.02 | −66.33% | $131.1M | SEC |
| Q1 2026 | May 14, 2026 | $0.05 | $0.04 | −25.65% | $128.3M | SEC |
| Q4 2025 | Feb 11, 2026 | $0.10 | $0.08 | −17.86% | $128.8M | SEC |
| Q3 2025 | Nov 12, 2025 | $0.09 | $0.08 | −15.34% | $126.0M | SEC |
| Q2 2025 | Aug 14, 2025 | $0.08 | $0.08 | +3.76% | $113.3M | SEC |
| Q1 2025 | May 14, 2025 | $0.05 | $0.07 | +33.33% | $107.5M | SEC |
| Q4 2024 | Feb 13, 2025 | $0.07 | $0.08 | +16.45% | $109.0M | SEC |
| Q3 2024 | Nov 6, 2024 | $0.07 | −$0.99 | −1425.30% | $106.9M | SEC |
| Q2 2024 | Aug 15, 2024 | $0.04 | −$0.12 | −430.58% | $95.7M | SEC |
| Q1 2024 | May 23, 2024 | $0.02 | −$0.36 | −1587.60% | $89.6M | SEC |
| Q4 2023 | Feb 15, 2024 | $0.03 | −$0.08 | −350.00% | $93.0M | SEC |
| Q3 2023 | Nov 14, 2023 | $0.03 | $0.03 | +17.19% | $84.2M | SEC |
| Q2 2023 | Aug 8, 2023 | $0.02 | −$0.17 | −1218.42% | $76.7M | SEC |
| Q1 2023 | May 10, 2023 | $0.01 | −$0.21 | −2758.23% | $71.2M | SEC |
| Q4 2022 | Feb 15, 2023 | $0.05 | $0.04 | −23.81% | $74.0M | SEC |
| Q3 2022 | Nov 17, 2022 | $0.01 | $0.13 | +2500.00% | $71.7M | — |
| Q2 2022 | Aug 11, 2022 | $0.01 | $0.17 | +1150.00% | $62.6M | — |
| Q1 2022 | May 12, 2022 | $0.01 | $0.27 | +2060.00% | $62.4M | — |
| Q4 2021 | Feb 16, 2022 | $0.02 | $0.25 | +1328.57% | $67.9M | — |
| Q3 2021 | Nov 10, 2021 | $0.01 | $0.08 | +1094.03% | $65.9M | — |
Quarterly revenue
Frequently asked questions
When did Cellebrite DI (CLBT) last report earnings?
Cellebrite DI last reported on Aug 13, 2026, covering fiscal Q2 2026.
Did CLBT beat earnings estimates?
No. Cellebrite DI reported EPS of $0.02 for Q2 2026 against a $0.06 estimate — a 66.33% miss.
How much revenue did CLBT report last quarter?
Cellebrite DI reported $131.1M in revenue for Q2 2026, against a consensus estimate of $131.5M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.